Tesla
TSLA
NVIDIA
NVDA
Palantir
PLTR
4
Apple
AAPL
5
Gorilla Technology
GRRR
US Stock MarketDetailed Quotes
RARE Ultragenyx Pharmaceutical
- 38.330
- +0.830+2.21%
Close Mar 11 16:00 ET
- 38.330
- 0.0000.00%
Post 16:05 ET
3.55BMarket Cap-6.09P/E (TTM)
38.655High37.260Low840.47KVolume37.530Open37.500Pre Close31.94MTurnover0.94%Turnover RatioLossP/E (Static)92.50MShares60.37052wk High13.89P/B3.42BFloat Cap37.02052wk Low--Dividend TTM89.31MShs Float179.647Historical High--Div YieldTTM3.72%Amplitude31.520Historical Low38.000Avg Price1Lot Size
About Ultragenyx Pharmaceutical Company
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.
Company Profile
SymbolRARE
Company NameUltragenyx Pharmaceutical
Listing DateJan 31, 2014
Issue Price21.00
Founded2010
CEODr. Emil D. Kakkis, M.D.,PhD
MarketNASDAQ
Employees1294
Fiscal Year Ends12-31
Address60 Leveroni Court
CityNovato
ProvinceCalifornia
CountryUnited States of America
Zip Code94949
Phone1-415-483-8800
Websitehttp://www.ultragenyx.com
Company Executives
- Name
- Position
- Salary
- Dr. Emil D. Kakkis, M.D.,PhD
- Director, President and Chief Executive Officer
- 13.08M
- Theodore A. Huizenga
- Senior Vice President, Corporate Controller and Chief Accounting Officer
- --
- Erik Harris
- Chief Commercial Officer and Executive Vice President
- 4.07M
- Howard Horn
- Chief Financial Officer and Executive Vice President, Corporate Strategy
- 5.94M
- Thomas R. Kassberg
- Chief Business Officer and Executive Vice President
- --
- Dr. Eric Crombez, M.D.
- Executive Vice President and Chief Medical Officer
- --
- Karah Parschauer
- Chief Legal Officer and Executive Vice President, Corporate Affairs
- 4.04M
- John Richard Pinion, II
- Chief Quality Officer and Executive Vice President, Translational Sciences
- 4.05M
- Dennis Karl Huang
- Chief Technical Operations Officer and Executive Vice President, Gene Therapy Operations
- --
- Daniel G. Welch
- Chairman of the Board
- 499.89K
- Matthew K. Fust
- Independent Director
- 479.89K
- Dr. Shehnaaz Suliman, M.D.
- Independent Director
- 466.89K
- Dr. Corazon Dating Sanders, PhD
- Independent Director
- 469.39K
- Dr. Deborah L. Dunsire,M.D.
- Independent Director
- 459.89K
- Michael A. Narachi
- Independent Director
- 482.39K
- Dr. Amrit Ray, M.D.
- Independent Director
- 460.39K